Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

B-TEMIA and Wistron Sign Investment Agreement


Posted on: 12 Sep 17

QUÉBEC CITY, Sept. 12, 2017 (GLOBE NEWSWIRE) -- B-TEMIA Inc., a Canadian biorobotic tech company and leader in the human augmentation market with its proprietary Dermoskeleton™ technology to aid mobility and Wistron Corporation, one of the world’s largest original design and manufacturers (ODMs) with revenues over CAD 25.5 billion, have signed an investment agreement whereby Wistron becomes a major shareholder in B-TEMIA.  Wistron will be represented on B-TEMIA’s Board of Directors and will be involved in the manufacturing, development and commercialization of B-TEMIA’s current and future products.  The prominent role of Wistron in the manufacturing process of B-TEMIA’s products for the subsequent commercialization phases means assured global market supply of top quality life-changing technology, such as Keeogo™.

“B-TEMIA’s Dermoskeleton™ technology was developed to address a global need for human mobility. Our first product, the Keeogo™ wearable robotics, using advanced artificial intelligence proprietary software, helps people with mobility limitations caused by diseases and conditions such as multiple sclerosis, Parkinson’s, knee/hip osteoarthritis, and stroke to move with strength and stability enabling them to regain their autonomy.  Aligned strongly with our corporate strategy for our next growth phase, we are very pleased to collaborate with Wistron to further expand the market reach of this advanced technology,” stated Stéphane Bédard, CEO of B-TEMIA.

“We are proud of collaborating with a company like B-TEMIA that has developed this innovative technology which benefits the lives of many individuals with impaired mobility, and their caregivers.  Investing in B-TEMIA is a cornerstone of Wistron’s strategic move into the medical industry, and one that has immediate impact on our goal to help improve people’s lives,” added Donald Hwang, CTO of Wistron Corporation.

About the Keeogo™ Dermoskeleton™
Keeogo™ is a powered walking assistance device developed by B-TEMIA.  Keeogo™, which implies “Keep on going”, has been used by individuals with degenerative medical conditions such as knee/hip osteoarthritis, multiple sclerosis, Parkinson’s disease, stroke, incomplete spinal cord injury (SCI) and other conditions that limit mobility.  Used as rehabilitation equipment or as a device at home to aid with daily activities, Keeogo™ is commercially available in Canada for purchase or rental.  It is currently under investigation in a multicenter pivotal clinical trial aiming for Food and Drug Administration (FDA) clearance, a prerequisite to enter the US market.

About B-TEMIA
Founded in 2010, B-TEMIA Inc. is an innovative Canadian medical device manufacturer that develops and markets cutting-edge products for the growing market of human augmentation systems. B-TEMIA operates through two wholly-owned subsidiaries, B-TEMIA Inc. and B-TEMIA USA Inc., in the medical, industrial and military fields. B-TEMIA owns a patented technology called Dermoskeleton™ that restores, maintains or enhances the mobility of users.  For more information, please visit: www.b-temia.com.

About WISTRON
Wistron Corporation is among the world’s largest companies producing products such as servers and storage devices for cloud computing and data centers, enterprise and consumer desktop and laptop PCs, smartphones, rugged industrial devices and control units, medical devices and big data analytics, smart home and smart retail IoT products, AR/VR, green recycling, etc.  Wistron’s full array of engineering teams allows Wistron’s customers to outsource some or all of their product development and manufacturing tasks to focus on their core competence and further develop intellectual properties.  Wistron manufactures medical products for medical industry customers in two ISO 13485 certified factories, located in the Hsinchu Science Park in Taiwan and in Chongqing, China.  For more information, please visit: www.wistron.com.

Information

Source:                                                    
B-TEMIA Inc.
4780, St-Félix Street
St-Augustin (Québec) G3A 2J9
www.b-temia.com | www.keeogo.com
Phone: (418) 653-1010
E-mail: info@b-temia.com
Media:
Stephane Bedard
CEO
Phone: (418) 653-1010, ext. 223
E-mail: stephane.bedard2@b-temia.com

 
GlobeNewswire
globenewswire.com

Last updated on: 13/09/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.